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The aim of this study was to obtain evidences of a possible analgesic role for palmitoylethanolamide (PEA) in
chronic granulomatous inflammation sustained by mast cell (MC) activation in rats at 96 hours. PEA (200-400-
800 μg/mL), locally administered at time 0, reduced in a concentration-dependent manner the expression and
release of NGF in comparison with saline-treated controls. PEA prevented nerve formation and sprouting, as shown
by histological analysis, reduced mechanical allodynia, evaluated by Von Frey filaments, and inhibited dorsal root
ganglia activation. These results were supported by the evidence that MCs in granuloma were mainly degranulated
and closely localized near nerve fibres and PEA significantly reduced MC degranulation and nerves fibre formation.
These findings are the first evidence that PEA, by the modulation of MC activation, controls pain perception in an
animal model of chronic inflammation, suggesting its potential use for the treatment of all those painful conditions
in which MC activation is an initial key step.
Introduction
Mast cells (MCs) are well recognized as a “body guard”
in host defense reactions, as inducers of innate and
acquired immunity and tissue remodelling, because of
their pivotal role in initiating allergic reactions. More-
over, in recent years, MCs have also been acknowledged
to modulate the inflammatory process [1]. Their contri-
bution to neuro-immune processes remains, however,
less clear. There are many independent lines of evidence
that indicate massive, bidirectional cross-talk between
MCs and sensory nerves (SNs) suggesting that MCs and
SNs may be functionally [2] and anatomically assembled
within certain tissues [3,4]. In the skin, for instance,
MCs are frequently co-localized with nerve fibres
expressing substance P (SP) and calcitonin gene-related
peptide (CGRP) and/or other peptidergic mediators [5];
moreover, activated MCs produce and release histamine,
serotonin, and tryptase leading to SNs activation thus
contributing to neurogenic inflammatory reactions [6].
Above all, MCs by releasing NGF and TNF-a,a r e
thought to regulate SNs development, degeneration, and
regeneration [7,8]. Therefore, MCs and SNs have been
suggested to co-orchestrate a variety of physiological
and pathological processes, such as hair follicle cycling,
wound healing, stress responses and to contribute to
the pathogenesis of inflammatory and autoimmune
diseases [9,10].
In several animal models of inflammatory pain, includ-
ing complete Freund’s adjuvant-induced arthritis [11],
carrageenin-induced paw oedema [12] and a rat model
of cystitis [13,14], NGF expression was found to be
increased. Moreover, it has been shown that over-
expression of NGF results in a marked nerve fibre
hyperplasia in the urinary bladder submucosa [15].
Recently, the administration of a new molecule seques-
trating endogenous NGF has shown to reduce acute and
chronic inflammatory processes and associated pain
[16]. These studies suggest that peripherally produced
NGF is involved in the development and maintenance
of nociceptive sensory neuron sensitivity and that an
up-regulation of NGF is responsible for alterations in
pain-related behaviour [17]. Therefore, blockade of NGF
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novel strategy to avoid nerve hypersensitivity induced by
inflammation, and possibly as a novel non-canonical
anti-inflammatory analgesic drug [18].
A class of molecules potentially able to control NGF
synthesis and release is represented by ALIA compounds
(from the acronym Autacoid Local Injury Antagonist),
naturally-occurring lipid amides deriving from mem-
brane fatty acids and structurally related to endocannabi-
noids. Palmitoylethanolamide (PEA) is considered the
most important of the ALIAmides because of its ability
to negatively modulate MC activation [19,20].
Although considerably more abundant than the endo-
cannabinoid anandamide (arachidonoyl ethanol amide:
AEA) or 2-arachidonoylglycerol (2-AG) in many tissues,
the effects of PEA are less well know than those of AEA
or 2-AG, probably due to its puzzling mechanism of
action. In fact, PEA, although structurally related to
AEA is inactive at the cannabinoid CB1/CB2 receptor
site, but it exhibits several important pharmacological
effects shared with endocannabinoid compounds, such
as marked anti-inflammatory, anti-oedema and analgesic
properties in a wide range of experimental models of
inflammation [21]. There are several pieces of evidence
indicating that PEA might represent part of a “parallel”
endocannabinoid signalling system, with its own puta-
tive receptors.
To date, peroxisome proliferator-activated receptor-a
(PPAR-a) and G protein-coupled receptor 55 (GPR55)
have been suggested as endogenous putative receptors
for PEA, since their stimulation contributes to some of
PEA-induced anti-inflammatory and analgesic effects.
Moreover, it has been demonstrated that PEA signifi-
cantly reduces peripheral pain through a mechanism
that is enhanced by AEA and blocked by CB2 receptor
antagonists [16]. The mechanism through which PEA
exerts its anti-nociceptive effects remains unclear since
it does not interact with the CB2 receptor. Therefore, it
has been postulated that this compound might evoke
analgesia through a still uncharacterized CB2-like recep-
tor [16], probably expressed specifically on MCs [19].
Alternatively, several important actions of PEA seem to
be mediated by none of these receptors, but indepen-
dently of any receptor activation [22].
Therefore, the aim of our study was to investigate the
anti-inflammatory and/or anti-allodynic properties of
PEA in a model of chronic inflammation actively sus-
tained by MC involvement, such as subcutaneous granu-
loma formation induced by l-carrageenin in rats.
Moreover, we evaluated the capability of PEA in reducing
the granuloma-induced enhancement of pro-inflamma-
tory mediators in neural and satellite cells of dorsal root
ganglia (DRG) innervating granulomatous areas.
Materials and methods
Animals
Male Wistar rats (Harlan, Italy), weighing 200-220 g,
were used in all experiments. Animals were housed three
per cage under controlled illumination (12 h light/12 h
dark cycle; light on 06:00 h) and standard environmental
conditions (ambient temperature 20-22°C, humidity
55-60%) for at least 1 week before the beginning of the
experiments. Chow and tap water were available ad libi-
tum. Animal care as well as all experiments were in
accordance with European Community Council Directive
86/609/EEC and efforts were made to minimize animal
suffering and to reduce the number of animals used.
Sponge implantation surgery
Sponges were implanted as previously described by De Filip-
pis et al. [23]. Briefly, two polyether sponges (0.5 × 1.5 ×
2.0 cm and 0.035 ± 0.002 g), previo u s l ys t e r i l i z e db ya u t o c l a v -
ing for 20 min at 120°C, were subcutaneously implanted on
the back of rats (n = 12-18 for group) under pentobarbital
anesthesia (60 mg/kg). A volumeo f0 . 5m L / s p o n g eo fv e h i c l e
(saline), l-carrageenin (Sigma-Aldrich, St Louis, MO, USA)
1% w/v in pyrogen-free saline with or without 100 μl of PEA
solution (200, 400 and 800 μg/ml) was injected into each
sponge. Rats were sacrificed in an atmosphere of CO2 96 h
after the sponge implant. The tissue around the sponge
showing granuloma was dissected out, weighted, quickly
frozen in liquid nitrogen, and stored at -80°C.
Histological investigation
The granulomatous tissue around the sponge was
removed and fixed in 10% formalin. Paraffin-wax sec-
tions of thickness 4-6 μm were cut and stained with
toluidine blue for the evaluation of MCs and with hema-
toxil and eosin to study new nerve formation.
Western blot analysis
Granulomatous tissues were weighed and rapidly homo-
genized in 60 μl ice-cold hypotonic lysis buffer [10 mM
HEPES, 1.5 mM MgCl2,1 0m MK C l ,0 . 5m Mp h e n y l -
methylsulfonyl fluoride, 1.5 μg/mL soybean trypsin inhi-
bitor, pepstatin A 7 μg/mL, leupeptin 5 μg/mL, 0.1 mM
benzamidine, and 0.5 mM dithiothreitol (DTT)] and
incubated on ice for 45 min. After this, the cytoplasmic
fractions were obtained by centrifugation at 13000 g for
1 min and the protein concentration in the samples was
determined with a Bio-Rad assay kit according to the
manufacturer’s instructions. Immunoblotting analysis of
NGF, PGP 9.5 and tubulin were performed on a cytoso-
lic fraction of the cultured specimens. Cytosolic fraction
proteins were mixed with gel loading buffer (50 mM
Tris, 10% SDS, 10% glycerol 2-mercaptoethanol, 2 mg/mL
bromophenol) in a ratio of 1:1 v/v, boiled for 5 min and
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tion was determined and equivalent amounts (50 μg) of
each sample were separated under reducing conditions on
12% SDS-polyacrylamide minigel. The proteins were
transferred onto a nitrocellulose membrane according to
the manufacturer’s instructions (Bio-Rad Laboratories,
Hercules, CA, USA). Depending on the experiments, the
membranes were blocked by incubation at 4°C overnight
in high salt buffer (50 mM Trizma base, 500 mM NaCl,
0.05% Tween-20) containing 5% bovine serum albumin;
they were then incubated for 1 h with anti-NGF (1:100 v/v)
(Oncogene, San Diego, CA), anti-PGP 9.5 (1:2500 v/v)
(AbD Serotec, Oxford, UK) and anti-beta Tubulin
(1:1000 v/v) (Sigma Aldrich) for 2 h at room temperature,
followed by incubation with a specific horseradish peroxi-
dase (HRP)-conjugate secondary antibody (Dako, Golstrup,
DK). The immune complexes were developed using
enhanced chemiluminescence detection reagents (Amer-
sham, Italy), according to the manufacturer’s instructions
and developed by an Image-Quant Apparatus (GE Health-
care). The protein bands were scanned and densito-
metrically analyzed with a GS-800 imaging densitometer
(Bio-Rad Laboratories, CA, USA).
Assessment of mechanical allodynia
Rats were individually placed on an elevated plastic mesh
(1 cm
2 perforations) in a clear plastic cage and were
allowed to adapt to the testing environment for at least
15 min. Von Frey hairs (Semmes-Weinstein monofila-
ments, 2 Biological Instruments, Italy) with calibrated
bending forces (1.479, 2.041, 3.63, 5.495, 8.511, 11.749,
15.136 and 28.84 g) were used to deliver punctuate
mechanical stimuli of varying intensity. The von Frey hairs
were applied to the back of the rats, in the middle of and
around the granulomatous tissue formed. Each stimulus
was applied for approximately 1 s with an interstimulus
interval of 5 s. Withdrawal responses evoked by each
monofilament were obtained from five consecutive trials.
Voluntary movement, associated with the locomotion, was
not counted as a withdrawal response. Mechanical allody-
nia was defined as a significant decrease in the withdrawal
threshold to the von Frey hair application. A 28.84-g hair
sample was selected as the upper limit cut-off for testing.
Mechanical allodynia was also measured by counting the
frequency of withdrawals induced by 10 consecutive appli-
cations of the same Von Frey filament (26 g). Only robust
and immediate withdrawal responses to the stimulus were
considered as pain responses which were monitored for a
period of 60 min by experimenters who were blinded to
the treatment.
ELISA essay
ELISA essay was performed on supernatants of centri-
fuged implanted sponges. Nunc Maxisorp 96-well
microtiter plates (Gibco, Paisley, UK) were coated over-
night at 4°C with 1 μg/well of specific monoclonal anti-
body anti-NGF, diluted in 0.5 M Na2CO3.T h ew e l l s
were washed three times and then blocked with phos-
phate-buffered saline (PBS) containing 0.05% (v/v)
Tween 20 and 0.3% Fetal Bovine Serum (ELISA buffer)
for 30 min at room temperature. The standards and
samples in a volume of 100- μl were added then incu-
bated at 37°C for 1.5 h. The standard curve was gener-
ated using 0.1 ng to 1 μg/well of purified protein,
diluted in ELISA buffer. Following four washes with
ELISA buffer, the monoclonal antibodies were diluted
and added to the wells for 1 h. The wells were washed
four more times and then incubated for 1 h with the
secondary antibody: anti-mouse Ig, biotinylated species-
specific F(ab8)2 fragment from donkey (Amersham,
Milan, Italy), diluted 1:1000. Following a further four
washes, the wells were incubated for 1 h with 100 μl
streptavidinbiotinylated horseradish peroxidase complex
(Amersham, Milan, Italy) diluted 1:1000 (v/v) in ELISA
buffer. After a final six washes in ELISA buffer, 200 μl
of a 0.4 mg/mL solution of o-phenylenediamine dihy-
drochloride (OPD, Sigma, Italy) in 0.05 M phosphate
citrate buffer was added to each well and the colour was
allowed to develop for up to 10 min. The colour reac-
tion was stopped by addition of HCl and optical densi-
ties at 490 nm were measured using a microplate reader.
Immunohistochemistry
Under pentobarbital anaesthesia, animals were transcar-
dially perfused with saline solution followed by 4% paraf-
ormaldehyde in 0.1 M phosphate buffer. Dorsal root
ganglia (DRGs) were excised, post- fixed for 4 h in the
perfusion fixative, cryoprotected for 72 h in 20% sucrose
in 0.1 M phosphate buffer and frozen in O.C.T. embed-
ding compound. Transverse sections (12 μm) were cut
using a cryostat and thaw-mounted onto glass slides.
Slides were incubated overnight with primary antibody
solutions for the pro-inflammatory markers: TNF-a
(mouse anti-TNF-a 1:100 v/v, Sigma-Aldrich, Missouri,
USA.); NGF (mouse anti-NGF 1:100 v/v, Oncogene
Research Products, California, U.S.A) COX-2 (rabbit
anti-COX2, Santa Cruz, California, USA) co-labeled with
TRPV1 (goat anti-TRPV1, Santa Cruz, California, U.S.A);
satellite cells (rabbit anti-glutamine synthetase, Abcam,
Cambridge, UK). Following incubation, sections were
washed and incubated for 3 h with secondary antibody
solution (goat anti-rabbit, or donkey anti-rabbit or don-
key anti-mouse, IgG-conjugated Alexa FluorTM 488
and 568; 1:1000; Molecular Probes, USA). Slides were
washed, fitted with cover-slips with Vectashield mount-
ing medium (Vector Laboratories, USA) and examined
under a Leica fluorescence microscope. The double
staining using secondary antibody from the same source
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cation (TSA Plus Fluorescence System; PerkinElmer
Life and Analytical Sciences,M A ,U S A )[ 2 4 ] .An e g a t i v e
control, performed using the secondary antibody alone,
did not reveal any positive profile for all the markers
analyzed.
Statistical analysis
Results were expressed as the mean ± SEM of n animals
where each value is the average of responses in dupli-
cate sites. Statistical comparisons were made by T-Test
or one way-ANOVA followed by Bonferroni’st e s tf o r
multiple comparisons and p < 0.05 was considered to be
statistically significant. Pain responses to Von Frey hair
stimuli between different treated groups of rats were
performed using the Wilcoxon signed-ranks test and p <
0.05 was considered statistically significant.
In all set of experiments, analysis of linear regression
was performed to evaluate a concentration-dependent
relationship.
Results
Effect of PEA on l-carrageenin-activated mast cells
The histological analysis of l-carrageenin-induced granu-
loma tissue, stained with toluidine blue, showed a massive
degranulation of MCs (light blue stained cells, i.e.
degranulated MCs, in comparison to the deep blue stained
cells, i.e. non-degranulated MCs) compared with the saline
controls. A significant inhibition of MC degranulation in
granulomas of animals treated with PEA (800 μg/mL) was
obtained (Figure 1A). At high magnification, the histologi-
cal image of l-carrageenin-induced granulomatous tissues
showed that degranulated MCs were mainly localized not
only in the proximity of the blood vessels but were also in
close contact with nerves (Figure 1B).
Effect of PEA on l-carrageenin- induced NGF expression
NGF protein expression mainly released by activated
MCs, evaluated by Western blot analysis, was increased
in l-carrageenin granulomatous tissues compared with
saline controls; PEA treatment (200, 400, 800 μg/mL)
produced a concentration-dependent significant reduc-
tion in NGF protein expression (Figure 2A). PEA
treatment also significantly reduced, in a concentration-
dependent manner, the release of NGF in l-carragee-
nin-treated tissues, as measured by ELISA (Figure 2B).
Effect of PEA on the formation of new nerve fibres
Since the above findings showed the close proximity
of MCs to nerves, we went on to study the effect of
l-carrageenin-induced MCs mediator release on new
nerve fibres formation in granulomas. Histological
Figure 1 Effect of PEA on l-carrageenin-induced mast cell activation. “A” shows the effect of PEA on l-carrageenin-induced mast cell (MC)
activation. MC degranulation was evaluated by microscopy. Connective MCs stained with 0.05% (w/v) toluidine blue and counterstained with
0.1% (w/v) nuclear fast red (magnification 100×). A differentiation between non degranulated (deep blue) and degranulated (light blue) MC was
evaluable (a; b; c). In d) is shown the percentage of MC degranulation (ratio between degranulated and non degranulated MC). Results are
expressed as mean ± SEM of 3 experiments. ***p < 0.001, °°p < 0.01. “B” shows high magnification of a representative histological analysis of
granulomatous tissues stained with toluidine blue in which the presence of degranulated MCs is clearly visible close to blood vessels and nerves.
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lin/eosin showed in the l-carrageenin group an altered
presence, shape and size of the nerve fibres, in compari-
son with saline controls that was restored by treatment
with PEA (800 μg/mL) (Figure 3A).
The decrease in neurogenesis produced by PEA was
also paralleled, thus confirmed, by a reduction in PGP
9.5 protein expression, a cytoplasmic protein present
in neurons and neuroendocrine cells, which could be
usedto visualize several different populations and
Figure 2 Effect of PEA on l-carrageenin-induced NGF expression and release in granulomatous tissue r 96 h after PEA administration.
(A) Representative Western blot analysis and relative densitometric analysis of NGF. Tubulin expression is shown as a control. (B) ELISA assay of
NGF release in granulomatous tissue. Data are representative of 3 separate experiments. Results are expressed as mean ± SEM of 3 experiments.;
*p < 0.05, **p < 0.01, ***p < 0.001 vs. saline.; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs. l-carrageenin alone.
Figure 3 Effect of PEA on l-carrageenin-induced neurogenesis. (A) Nerves formation was evaluated in representative histological analysis of
granulomatous tissue stained with hematoxyl and eosin. Fields are representative of 3 separate experiments. Original magnification, 100×. (B)
Representative Western blot analysis and relative densitometric analysis of PGP 9.5 protein expression, as a marker of neuronal cells. Results are
expressed as mean ± SEM of 3 experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. saline; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs. l-carrageenin
alone.
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PEA (200, 400, 800 μg/mL) acted in a concentration-
dependent manner to reduce l-carrageenin-induced
PGP 9.5 expression (Figure 3B).
Effect of PEA on mechanical allodynia
We then tested the pain response occurring in l-carra-
geenin-induced granuloma with Von Frey filament mea-
s u r i n gt h ep a i nr e s p o n s ee v o k e db yt h ea p p l i c a t i o no f
different target forces, both centrally and externally to
granulomas compared with saline-treated control rats.
The treatment with PEA (800 μg/mL) markedly reduced
pain responses both at the centre of and externally to
granulomatous tissue, showing that this compound is
able to control inflammatory pain (Figure 4A). The
analgesic properties of PEA were then confirmed by its
efficacy in reducing the frequency of withdrawals
induced by 10 consecutive applications of the same tar-
get force Von Frey filament (Figure 4B).
Effect of PEA on DRGs biomolecular and morphological
changes
We evaluated the effect of l-carrageenin-induced granu-
loma on the biomolecular and morphological changes in
the dorsal root ganglia (DRGs) directly receiving sensory
input from dermatomera (skin segments) affected by
granuloma formation. We found that granuloma-
induced mechanical allodynia was associated with
increased expression of the pro-inflammatory markers
TNF-a, NGF and COX-2 in the DRGs. All these protein
levels were significantly reduced by PEA treatment as
revealed by Western blot analysis (Figure 5). We used
an immunohistochemical approach in order to investi-
gate the citotypes involved in the granuloma-induced
DRGs sensitization. Our results showed that TNF-a and
NGF were expressed by neurons as revealed by double
labeling with transient receptor potential vanilloid 1
(TRPV1) expressed by nociceptive neurons in the DRG
[25] (Figure 5A, B), while COX-2 was highly expressed
by satellite glial cells as shown by glutamine synthetase
staining (Figure 5C).
Discussion
Based on our previous reports regarding the ability of
PEA [22] and its analogue, Adelmidrol [23], to prevent
granuloma formation by the control of MC activation in
rats, the study described in the present paper was aimed
to extend our knowledge about the pharmacological
effects of PEA, focusing on mechanical allodynia that
may occur during chronic inflammatory conditions
[22,23]. The histological analysis of granulomatous tissue
highlighted a massive presence of degranulated MCs, not
only closely associated with blood vessels, as previously
described by us [23], but also in tight contact with nerve
fibres. This last observation was in accordance with
another study hypothesizing that there is a close relation-
ship between MCs and nerve fibres occurs in modulation
of neuronal plasticity [2]. Accordingly, we also investi-
gated the effect of PEA, based on the well described con-
trol of MC activation, on nerve fibre activity in
granuloma. Similarly to Adelmidrol, indeed, PEA admin-
istration reduced MC activation and the subsequent
release of bioactive mediators within and around granu-
lomatous tissue [1]. Particular emphasis, in this paper,
was given to NGF derived from MCs, which is considered
one of the key mediators of neuronal plasticity and nerve
fibre sensitization [26,27]. The role exerted by NGF in
pain signaling is now well understood: low doses of NGF
Figure 4 Effect of PEA on l-carrageenin-induced hyperalgesia. Mechanical allodynia was evaluated by von Frey filament as (A) a target force
both centrally and externally to granulomatous tissue and as (B) the frequency of withdrawals induced by 10 consecutive applications of the
same von Frey filament. Results are expressed as mean ± SEM of 3 experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. saline; °p < 0.05, °°p <
0.01, °°°p < 0.001 vs l-carrageenin alone.
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rodents, thermal and mechanical hyperalgesia develops
after systemic NGF administration [28]; moreover, NGF
produces sensitization of nociceptors both directly (after
activation of its specific receptors on nociceptive fibres)
and indirectly, through other peripheral cell types. The
direct mechanism involves both altered gene expression
and post-translational regulation of receptors, including
TRPV1 [29]. Moreover, NGF can trigger a number of
peripheral immune cell types expressing trkA, including
MCs. In fact, NGF can produce degranulation and
increase proliferation of MCs [30], resulting in an auto-
crine/paracrine loop that sustains inflammation and
hyperalgesia [31]. Our data showed that PEA, by modu-
lating MC degranulation, reduced, in a concentration-
dependent manner, NGF protein expression and release
in the chronically inflamed tissues. The reduction in
NGF exerted by PEA in our model can be explained with
different mechanisms of action, an ALIA mechanism
played on MCs present in granulomatous tissues in
accordance with the original hypothesis proposed by
Facci et al. [19], or by the “entourage effect” operated by
Figure 5 Effect of PEA on DRG biomolecular and morphological changes induced by granuloma. The effect of granulomatous
inflammation on the biomolecular and morphological changes in the DRGs was associated with increased expression of TNF-a (A), NGF (B) and
COX-2 (C). The levels of all proteins studied were significantly reduced by PEA treatment as revealed by Western blot analysis (A, B and C upper
panels). Our results show that TNF-a and NGF were expressed by neurons as revealed by double labeling with TRPV1 receptor expressed in the
DRG (A and B bottom panel) while COX-2 was highly expressed by satellite glial cells identified by glutamine synthetase staining (C bottom
panel). Results are expressed as mean ± SEM of 3 experiments. ***p < 0.001 vs saline; °°°p < 0.001 vs l-carrageenin alone.
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or TRPV1 receptors as previously demonstrated in a
model of neuropathic pain by Costa et al. [32] or, finally,
by the binding to an orphan receptor also expressed
on mast cells, the G-protein coupled receptor-55
(GPR-55) [33].
The effect of PEA on NGF release leads to a reduction
in the number of nerve fibres in l-carrageenin-induced
granulomatous tissue. These results are consistent with
the well known role of NGF, able to produce nerve
sprouting within and close to injured tissue [34], an
effect due to the neurotrophic ability of NGF to affect
neuronal growth, neuronal survival and axonal out-
growth [8]. The decrease in the number of nerve fibres
observed in the histological analysis of PEA-treated
animals was also seen to occur in parallel with a con-
centration-dependent decrease in PGP 9.5 protein
expression, a cytoplasmic protein present in neurons
and neuroendocrine cells, useful to visualize several
different populations and subtypes of nerves, which con-
firmed our previously discussed results.
Therefore, it seems possible to justify the lower pain
sensitivity exhibited by rats treated with PEA consider-
ing the reduced number of nerve fibres obtained with
PEA treatment which is associated with a decrease in
NGF. In fact, NGF is considered to be not only a pro-
moter of neuronal sprouting, but it is also involved in
neural sensitization since it increases the excitability and
the firing of sensory neurons [35-37]. Our results are in
agreement with previous data showing that administra-
tion of PEA produces antinociception in the formalin
test [38], reduces inflammatory hyperalgesia and oedema
by inhibiting MC degranulation [39] and inhibits
mechanical hyperalgesia after intraplantar carrageenin
challenge in animals [40]. Moreover, the results reported
in the present study are consistent with a recent study
demonstrating that the anti-hyperalgesic action of PEA
in a model of neuropathic pain depends, at least in part,
on the reduction in NGF up-regulation [32].
Growing evidences indicate the role of glial and
microglial cells in the induction and maintenance of
pathological pain-associated allodynia. Also at DRG
level, the satellite glial cells, which in fact represent the
peripheral glial cells (astrocytes), seem to play a key role
in the maintenance of neuropathic pain-associated
mechanical allodynia [41].
Further insight can be obtained into PEA analgesic
effects since it was also able to prevent DRG neural sensiti-
zation, here indirectly suggested by immunohistochemistry
and western blotting for TNF-a and NGF, as well as the
COX-2 in satellite cells. In fact, a significant increase in
TNF-a, NGF and COX-2 was found in DRGs isolated in
granuloma from rats treated with l-carrageenin, compared
with control animals. Interestingly, double staining images
showed that TNF-a and NGF have TPRV1-positive pro-
files, corresponding to neurons [25], while COX-2 protein
was expressed by satellite glial cells in DRGs. These results
underline the fact that the induction of granulomatous tis-
sue triggers significant functional changes in DRG neurons
which is also corroborated by the involvement of satellite
cells in releasing pro-inflammatory molecules. In actual
fact, NGF itself has been shown to sensitize dorsal horn
neurons after intramuscular injection [42]. PEA, by switch-
ing off the inflammation in l-carrageenin-induced granu-
loma formation, might be responsible for the inhibition of
DRG neuronal sensitization, as suggested by the reduced
expression of NGF, COX-2 and TNF-a,a sw e l la sb yt h e
decreased mechanical allodynia in animals treated with
PEA. These observations are consistent with a previous
study demonstrating that intraplantar administration of
PEA preferentially suppresses spinal neuronal sensitization
evoked by hindpaw formalin administration [43].
Hence, the present data support an analgesic role
played by PEA in several models of pain, like persistent
somatic inflammatory pain, visceral inflammatory pain
and neuropathic pain, and recognize, for the first time,
in MCs the leading cell-type affected by PEA in this
model of chronic inflammation-dependent pain [44].
Thus, according to our results it is reasonable to pro-
pose the use of PEA and its congeners in the treatment
of several painful conditions, especially those involving
MC degranulation and NGF release.
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